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Abstract
Background: Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive
value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes
far longer, and the interpretation of biomarker findings is particular relevant for individuals who present at a memory
clinic, but are deemed cognitively normal. The objective of the current study is to construct biomarker-based prognostic
models for personalized risk of clinical progression in cognitively normal individuals presenting at a memory clinic.
Methods: We included 481 individuals with subjective cognitive decline (SCD) from the Amsterdam Dementia Cohort.
Prognostic models were developed by Cox regression with patient characteristics, MRI, and/or CSF biomarkers to predict
clinical progression to MCI or dementia. We estimated 5- and 3-year individualized risks based on patient-specific values.
External validation was performed on Alzheimer’s Disease Neuroimaging Initiative (ADNI) and an European dataset.
Results: Based on demographics only (Harrell’s C = 0.70), 5- and 3-year progression risks varied from 6% [3–11] and 4%
[2–8] (age 55, MMSE 30) to 38% [29–49] and 28% [21–37] (age 70, MMSE 27). Normal CSF biomarkers strongly decreased
progression probabilities (Harrell’s C = 0.82). By contrast, abnormal CSF markedly increased risk (5 years, 96% [56–100];
3 years, 89% [44–99]). The CSF model could reclassify 58% of the individuals with an “intermediate” risk (35–65%) based
on the demographic model. MRI measures were not retained in the models.
Conclusion: The current study takes the first steps in a personalized approach for cognitively normal individuals by
providing biomarker-based prognostic models.
Keywords: Biomarkers, Progression, Cerebrospinal fluid, Magnetic resonance imaging
Background
Dementia disorders place a huge burden on society and are
set to bulge due to an aging population [1, 2]. Alzheimer’s
disease (AD) is the most common cause of dementia and
represents the largest unmet medical need in neurology
[3]. In order to bring therapy and support to individuals as
timely and accurate as possible, diagnostic tests play a key
role. In individual patients with mild cognitive impairment
(MCI), biomarkers such as cerebrospinal fluid (CSF) and
magnetic resonance imaging (MRI) have been shown to
have predictive value for progression to dementia [4].
However, the pre-dementia stage of AD takes far longer, as
neuropathological changes already start in the cognitively
normal stage [3, 5–8]. For that reason, recent criteria
proposed a biological framework for AD in which AD is
classified based on the presence of pathology rather than
the presence of clinical symptoms [8].
On a group level, AD biomarkers are predictive in
cognitively normal individuals as well. For example, a re-
duced hippocampal volume on MRI has been associated
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with an increased risk of clinical progression [9–11].
Furthermore, an abnormal AD biomarker profile in CSF
has been shown to be strongly associated with clinical
progression [12–16]. Moreover, even relatively low amyl-
oid β1–42 (Aβ) levels, yet within the normal range, have
been associated with clinical progression, indicating that
simple dichotomous cutoffs fail to extract all information
available in these markers and moreover may erroneously
reassure individuals [17].
The question how these findings on group level translate
to the individual is particular relevant for individuals who
present with worries about their memory at a memory
clinic, but are deemed cognitively normal. Unfortunately,
findings on group level cannot be translated directly to the
individual and the interpretation of biomarkers is not opti-
mized. In addition, the meaning of biomarkers should
ideally be interpreted in the context of an individual’s own
characteristics [18], but information on how to weigh and
combine multiple sources of information is lacking. Therefore,
clinicians are generally reluctant to disclose biomarker results
to cognitively normal individuals. Nonetheless, individuals
and caregivers become increasingly assertive, demanding
more specific and individually tailored information [19].
The objective of this study was to optimize the inter-
pretation of biomarkers by composing individualized
prediction models for clinical progression to MCI or de-
mentia based on MRI and/or CSF biomarkers that could
be used in cognitively normal individuals.
Methods
Participants
We included 481 cognitively normal individuals from
the Amsterdam Dementia Cohort (ADC) and ongoing
SCIENCe project, with a baseline diagnosis of subjective
cognitive decline (SCD), available baseline MMSE, and
available baseline MRI and/or CSF data [20, 21]. All in-
dividuals had their baseline visit in our memory clinic
between January 2000 and November 2015. Individuals
with a diagnosis of MCI or dementia within 6 months
after baseline were excluded from the analysis as they
were likely to have been misclassified at baseline.
Baseline diagnostic work-up consisted of a standardized
1-day dementia screening [20, 21]. Clinical diagnosis was
made by consensus in a multi-disciplinary meeting. Indi-
viduals were labeled with SCD if they presented with cogni-
tive complaints, had normal results on clinical assessments,
and did not meet criteria for MCI, dementia, or any other
neurologic or psychiatric disorder known to cause cognitive
complaints (i.e., cognitively normal) [22].
Standardized annual follow-up included a follow-up visit
with the neurologist and neuropsychologist, and diagnoses
were re-evaluated in a multi-disciplinary meeting [20]. Until
early 2012, MCI was diagnosed according to Petersen’s cri-
teria and from 2012 onwards, the diagnosis of MCI was
based on National Institute on Aging-Alzheimer’s Association
(NIA-AA) criteria [23, 24]. The diagnosis of AD dementia
and other types of dementia was based on international
diagnostic or research consensus criteria [25–28].
MRI
Before 2008, brain MRI was performed on 1.0 and 1.5T
MRI systems (Siemens Magnetom Avanto, Vision, Impact
and Sonata, GE Healthcare Signa HDXT). From 2008 on,
MRI of the brain was performed on 3T MRI systems
(MR750, GE Medical Systems, Ingenuity TF PET/MR, Phi-
lips Medical Systems; Titan, Toshiba Medical Systems).
The standard dementia protocol with whole brain coverage
included near-isotropic sagittal 3D T1-weighted images
(including oblique coronal reconstructions), sagittal 3D
T2-weighted fluid-attenuated inversion recovery (FLAIR)
(including axial reconstructions), axial T2-weighted turbo
spin-echo, and axial T2*-weighted gradient echo sequence
or alternatively SWI sequences. MRI data was available for
432 (90%) individuals.
Bilateral hippocampal volume (HCV, mL) was estimated
using FMRIBs Integrated Registration and Segmentation
Tool (FIRST) [29]. Normalized brain volumes (NWBV,
mL) were estimated with SIENAX (Structural Image Evalu-
ation using Normalization of Atrophy Cross-sectional)
using optimized settings [30]. Additionally, visual rating of
MRI was performed according to semi-quantitative visual
rating scales for medial temporal lobe atrophy (MTA, 0–4)
and global cortical atrophy (GCA, 0–3) [31, 32].
CSF analysis
CSF was obtained by lumbar puncture and collected in
polypropylene tubes (Sarstedt, Nurmberg, Germany) and
processed according to international guidelines [33]. CSF
biomarkers Amyloid β1–42 (Aβ) and total Tau (tau) were
measured using sandwich enzyme-linked immuno sorbent
assay (ELISA) on a routine basis (Innotest, Fujirebio, Gent,
Belgium) [34]. Baseline CSF data was available for 344
(72%) individuals.
Statistical analysis
All analyses were carried out in STATA 14SE. Prognostic
models were constructed with Cox regression analysis
(determinants as continuous measures; CSF biomarkers
log-transformed). The models were constructed with
complete cases only, and therefore, the number of indi-
viduals varied across models. No differences in demo-
graphic characteristic or baseline survival were found
between individuals with complete data and incomplete
data (Additional file 1: Table S1). The clinical end-point
was MCI or dementia [23–28].
First, a prognostic model based on patient characteristics
(age, gender, and MMSE) and interactions between the
characteristics was constructed. Subsequently, we added
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either MRI biomarkers (volumetric measures: HCV,
NWBV, or visual ratings: MTA, GCA), CSF biomarkers
(Aβ, Tau), or both to the model. The models with volumet-
ric MRI measures were adjusted for field strength. In all
analyses, we intensively investigated main effects of patient
characteristics and interaction effects between biomarkers
and between biomarker and patient characteristics. Effects
were retained in the model via a backward selection pro-
cedure, if p value ≤ .10. The prognostic accuracy of the
model was measured by Harrell’s C-statistic.
We estimated cumulative progression probabilities with
95% confidence intervals using the survci command in
STATA [35]. We report 5-, 3-, and 1-year cumulative pro-
gression probabilities with corresponding confidence in-
tervals. Since the clinical follow-up visit times showed
some variation, the cutoff for 1-year follow-up was set at
1.5 years, for 3-year follow-up at 3.5 years, and for 5-year
follow-up at 5.5 years. As an example, we provide risk esti-
mates for individuals with an age of 55 and 70; females
and males and MMSE scores of 30 or 27. To contrast in-
dividuals with normal and abnormal MRI and CSF results,
we entered 10th and 90th percentile MRI and CSF values
in the Cox model. Note that when using the models, any
value can be entered for a variable. Based on the
constructed models, 5-year progression probabilities were
calculated for every patient in the cohort. Subsequently,
we labeled each individual as having low risk (≤ 35%),
intermediate risk (35–65%), or high risk (> 65%).
In an additional set of analyses, we repeated all ana-
lyses to construct models predicting progression to MCI
or AD dementia as clinical end-point. In this set of ana-
lyses, individuals progressing to non-AD were censored
at time of diagnosis of non-AD dementia.
Validation
We internally validated the models by five-fold cross-valid-
ation, in which we again applied a backward selection
procedure.
Next, we performed external validation of our models
on a sample comprising individuals with SCD from Alz-
heimer’s Disease Neuroimaging Initiative (ADNI, n = 92),
Dementia Competence Network (DCN, n = 86), and Bar-
celona Memory Clinic (n = 41). Like the ADC cohort,
DCN and Barcelona included individuals that went to the
memory clinic to seek medical help and were labeled with
SCD when cognitive testing could not confirm their cog-
nitive complaints, and criteria for MCI, dementia, or other
neurological or psychological diseases were not met.
ADNI on the other hand is a population-based study. Sub-
jects were labeled with SCD when a significant subjective
memory concern was reported by the subject, informant,
or clinician.
CSF was measured with Innotest in the DCN and Bar-
celona cohort and with Elecsys in ADNI. Therefore,
biomarker values were standardized for the analysis to
remove measurement levels. Patient characteristics from
the cohorts can be found in Additional file 1: Table S2.
Differences between the cohorts included a higher age in
the ADNI cohort, higher progression rates in the DCN,
longer follow-up for ADC and Barcelona individuals;
and ADNI and Barcelona individuals were more often
female (Additional file 1: Table S2). Established models
were fitted to the validation data, and Harrell’s C-statis-
tics were calculated.
Results
During a mean follow-up of 3 ± 2 years, 70 (15%) individ-
uals showed clinical progression to MCI (n = 49), AD
dementia (n = 10), or non-AD dementia (n = 11). Mean
age was 62 ± 9 years, 211 (44%) of the individuals were
female, and the mean MMSE score was 28 ± 1.6 (Table 1).
Table 2 shows the variables and corresponding coeffi-
cients included in the models (demographics only, CSF
model, MRI volumetric model, and MRI visual model).
The demographics only model included age and
MMSE (sex not included, p value > .10). Harrell’s C-stat-
istic was 0.70 (Table 2). Younger individuals (as an
example, we set age at 55) with MMSE-scores of 30 had
a low risk of progression: after 5 years 6% [3–11],
after 3 years 4% [2–8], and after 1 year 2%[0–2]. On
the other end of the spectrum, older individuals (70)
with lower MMSE-scores (27) had higher progression
probabilities; risk of progression after 5 years was
38% [29–49], after 3 years 28% [21–37], and after
1 year 11% [7–16] (Table 3).
Table 1 Baseline characteristics
SCD individualsn = 481
No. (%) with clinical progression 70 (15%)
Progression to MCI 49 (10%)
Progression to AD dementia 10 (2%)
Progression to non-AD dementia 11 (2%)
Age 62 ± 9
Gender, no. (%) females 211 (44%)
MMSE 28 ± 1.6
Follow-up duration 3 ± 2
Medial temporal lobe atrophy 0.4 ± 0.5
Global cortical atrophy 0.4 ± 0.6
Hippocampal volume (cm3) 7.2 ± 1
Normalized whole brain volume (cm3) 1453 ± 100
Amyloid β1–42 879 ± 260
Total Tau 298 ± 196
p-tau 49 ± 22
Data are mean ± standard deviation, unless otherwise specified. MMSE mini-
mental state examination, MRI magnetic resonance imaging, CSF
cerebrospinal fluid
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Table 2 Regression coefficient of the final model
MCI/dementia MCI/AD-dementia
Coëfficient Standard error p value Harrell’s C Coëfficient Standard Error p value Harrell’s C
Demographic (n = 481)
Age 0.0854 0.0147 < .001 0.70 0.0904 0.0162 < .001 0.70
MMSE − 0.2497 0.0639 < .001 − 0.2236 0.0726 < .01
CSF (n = 344)
Aβ − 1.0462 0.3668 < .01 0.82 − 1.3941 0.4031 < .01 0.84
Tau 1.2785 0.3384 < .001 1.3829 0.4003 < .01
Age 0.0704 0.0251 < .01 0.0644 0.0296 < .05
Gender − 0.6360 0.3345 < .10 − 0.6375 0.3814 < .10
MMSE − 0.25503 0.0815 < .01 − 0.1846 0.0981 < .10
Tau* age − 0.1393 0.0467 < .01 − 0.1311 0.0534 < .05
CSF biomarkers (Aβ and Tau) are log-transformed and centered. MMSE mini-mental state examination, Tau* age interaction between age and Tau. Interaction term
was centered and standardized to allow inclusion in the model
Table 3 Progression probabilities after 1 year, 3 years, and 5 years
Demographics only CSF
Age Sex MMSE Normal AB abnormal Tau abnormal Both abnormal
1 year 55 m 30 2% [0–2] 0% [0–1] 0% [0–2] 12% [3–38] 26% [7–71]
27 3% [2–5] 0% [0–2] 0% [1–5] 26% [8–65] 51% [18–92]
f 30 2% [0–2] 0% [0–1] 0% [0–1] 6% [2–23] 15% [4–48]
27 3% [2–5] 0% [0–1] 0% [1–3] 15% [4–44] 32% [9–77]
70 m 30 5% [3–9] 5% [2–15] 13% [5–34] 4% [1–11] 8% [3–20]
27 11% [7–16] 12% [5–30] 29% [11–64] 9% [3–21] 19% [9–36]
f 30 5% [3–9] 3% [1–9] 7% [2–22] 3% [1–6] 5% [2–12]
27 11% [7–16] 7% [2–22] 16% [5–46] 5% [2–12] 10% [4–24]
3 years 55 m 30 4% [2–8] 0% [0–2] 1% [1–6] 32% [10–78] 60% [20–98]
27 9% [6–14] 1% [0–5] 2% [0–12] 60% [23–95] 89% [44–99]
f 30 4% [2–8] 0% [0–1] 1% [0–3] 19% [5–55] 39% [11–87]
27 9% [6–14] 0% [0–3] 1% [0–7] 39% [12–84] 69% [26–99]
70 m 30 15% [10–21] 16% [6–39] 35% [14–72] 13% [4–27] 23% [11–46]
27 28% [21–37] 33% [14–71] 64% [30–96] 24% [10–49] 48% [28–71]
f 30 15% [10–21] 9% [3–25] 21% [7–53] 7% [3–16] 16% [6–29]
27 28% [21–37] 21% [7–53] 43% [15–85] 14% [5–32] 29% [14–50]
5 years 55 m 30 6% [3–11] 1% [0–3] 1% [0–8] 43% [13–89] 73% [27–98]
27 12% [8–20] 1% [1–7] 4% [1–17] 73% [30–99] 96% [56–100]
f 30 6% [3–11] 0% [0–2] 1% [0–4] 25% [7–69] 51% [16–94]
27 12% [8–20] 1% [0–4] 2% [0–10] 50% [17–93] 81% [35–98]
70 m 30 20% [14–29] 22% [9–51] 47% [19–84] 17% [6–36] 32% [16–58]
27 38% [29–49] 44% [19–83] 78% [39–98] 32% [24–62] 60% [38–83]
f 30 20% [14–29] 13% [4–34] 28% [10–66] 10% [5–22] 21% [8–38]
27 38% [29–49] 28% [10–66] 55% [20–94] 20% [10–39] 39% [20–66]
Biomarker values were selected as 90th percentile (normal, −) and 10th percentile (abnormal, +); for Tau, 10th percentile was selected as normal (−) and 90th
percentile as abnormal (+). Note that this table is an example, as the model can provide individualized risk estimates for any given value. Data are % [95% CI]. For
CSF, −/− AB and Tau negative: +/− AB positive and Tau negative; −/+ AB negative and Tau positive; +/+ AB and Tau positive
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When we evaluated MRI markers, neither volumetric
nor visual measures added predictive value over the
demographic model including age and MMSE (p value
> .10). In the CSF model, female gender, higher age,
lower MMSE score, lower Aβ, and higher Tau values
were predictive of progression. Moreover, an interaction
between Tau and age is retained in the model. Tau was
more predictive than Aβ, especially in younger individ-
uals (Tau* age p value < .01, Table 3 and Fig. 1). Harrell’s
C-statistic was 0.82 (Table 2, similar when p-tau was
included instead of tau (Additional file 1: Table S3). To
contrast individuals with normal and abnormal CSF
results, we derived probabilities for individuals with 10th
and 90th percentile CSF values from the model.
Abnormal Aβ and Tau resulted in high 5-, 3-, and
1-year progression risks; 96% [56–100], 89% [44–99],
and 51% [18–92]. By contrast, normal CSF biomarkers
strongly decreased progression probabilities to 1% [0–3]
in 5 year, 0% [0–2] in 3 years, and 0% [0–1] in 1 year,
indicating the negative predictive value of these
biomarkers. Please note that we report examples, as the
model provides risks for any given value.
Figure 2 shows the distribution of 5-year progres-
sion probabilities based on the model including CSF
biomarkers. The majority of individuals, 84% (n =
290) were labeled as having low risk of progression,
12% (n = 41) had intermediate risk of progression,
and 4% (n = 13) had high risk of progression. Of
note, 58% of the individuals that were classified as
“intermediate” based on the demographic model
could be reclassified as having low (49%) or high
(9%) risk according to the CSF model (Add-
itional file 1: Table S4).
In an additional set of analyses, we repeated the
analysis restricting the outcome to progression to MCI
or AD dementia. The prognostic accuracy of the CSF
model increased in line with specificity for AD of the
biomarkers under evaluation. Harrell’s C-statistic
remained 0.70 for the demographic model and increased
to 0.84 for the CSF model.
Fig. 1 Probability isographs for 1-, 3-, and 5-year progression to MCI or dementia. Legend: Probability of progression within 1 (upper panel) year,
3 (middle panel) years, and 5 (lower panel) years based on Aβ (pg/mL, y-axis) and Tau (pg/mL, x-axis), stratified for individuals younger (left) and
older than 65 (right)
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Internal validation by five-fold cross-validation confirmed
prognostic performance in both models (Additional file 1:
Table S5); cross-validation of the demographic model
resulted in Harrell’s C-statistics ranging from 0.63–0.77.
The model with CSF biomarkers showed cross-validated
Harrell’s C ranging from 0.75–0.90.
External validation showed moderate performance of
the models (demographic model, Harrell’s C = 0.62; CSF
model, C = 0.68).
Discussion
In this study, we constructed biomarker prediction models
that provide individual risk estimates of clinical progres-
sion in order to optimize the interpretation of biomarkers
for cognitively normal SCD individuals. CSF biomarkers
considerably improved prognostic performance over the
use of age and MMSE only. This was mostly driven by
their strong negative predictive value.
Alzheimer pathology as reflected in biomarker changes
presumably starts more than 20 years before the onset of
dementia [3, 8]. Clinicians are reluctant to disclose bio-
marker results to cognitively normal individuals presenting
at a memory clinic, as former findings that were based on
group level cannot directly be translated to the individual.
Moreover, there is always a degree of uncertainty associ-
ated with the interpretation of biomarkers. With our
models, we provide a first step towards a framework for a
personalized approach, allowing the use of biomarker re-
sults for cognitively normal individuals presenting at mem-
ory clinics. This can be useful, as individuals and caregivers
become increasingly assertive in their need for information
on their risk of dementia. Moreover, interest in individual-
ized risk profiling and both primary and secondary preven-
tion strategies is increasing rapidly. Although truly
longitudinal data are lacking, our sample allowed to infer
predictions of progression over periods of 3 and even
5 years, which has great relevance for individuals and their
family members. Probabilities of progression within 1 year
in SCD individuals remain low, and this is in line with the
notion that outcome at 1-year follow-up is not a reason-
able time frame for SCD, as these individuals initially per-
form cognitively normal.
Former studies have shown the clinical relevance of
CSF biomarkers in pre-dementia individuals on a
group level [15, 16]. In the current study, we found
that Tau was a stronger predictor than Aβ. Particu-
larly, Tau was more predictive for progression in
younger individuals. Abnormal Tau values in older in-
dividuals were less predictive, probably due to normal
aging processes or multiple pathologies in older indi-
viduals [36]. Moreover, gender was included as a pre-
dictor in the CSF model, meaning that CSF measures
should also be interpreted in the context of a patient’s
gender. This fits with findings from a recently
published review that showed the importance of sex
differences for patient stratification and personalized
treatment [37]. With these CSF biomarkers and
patient characteristics, 88% of the individuals could
be classified as having a high (> 65%) or low (≤ 35%)
risk of clinical progression within 5 years.
Former studies on MRI biomarkers have reported that
cognitively normal individuals with SCD had lower hippo-
campal volumes compared to healthy controls [11]. More-
over, hippocampal atrophy and lower brain volumes
predicted of progression to MCI and/or dementia [10, 38].
However, these previously reported significant results for
MRI were mostly based on small absolute differences be-
tween groups of individuals, precluding their usefulness in
individualized risk predictions. In the current study, MRI
markers did not improve personalized risk estimates over
the use of age and MMSE only. The effects of MRI bio-
markers lost significance, as soon as age was included in
the model, suggesting that the observed atrophy in this
population is largely attributable to aging and/or did not
Fig. 2 Distribution of 5-year progression probabilities. Legend: Distribution of 5-year progression probabilities based on the CSF model. Green:
low risk 0–35%; orange: intermediate 35–65%; red: high risk 65–100%
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capture additional predictive value over subtle cognitive
impairment.
In a former study in MCI, we found that MRI biomarkers
in combination with patient characteristics and also CSF
biomarkers improve individualized prediction of progres-
sion to dementia [4]. The finding that atrophy on MRI has
less predictive value in cognitively normal individuals than
in MCI patients is consistent with the hypothetical bio-
marker model which suggests that CSF biomarker changes
precede MRI-based estimates of neurodegeneration [39].
Among the limitations, we found that the models
showed somewhat less prognostic performance in external
cohorts. This may be attributable to the fact that the out-
come in the current study is clinical progression to MCI
or dementia. While dementia is a relatively definitive
end-point, MCI patients may still remain stable or convert
to normal states of cognition and variability in this diagno-
sis between centers may be larger than in case of dementia
[3, 24, 40]. In addition, external validation is highly
dependent on the case-mix of a sample. In the field of
SCD, one of the most important unresolved challenges is
the variability of defining SCD across studies [41–43]. In
the ADC, DCN, and Barcelona cohort, all individuals went
to the memory clinic seeking help and their complaints
might be more severe than in the population-based ADNI
cohort. In ADNI, individuals were labeled with SCD when
a significant subjective memory concern was reported by
the subject, informant, or clinician. Moreover, the stan-
dardized diagnostic work-up differed between the centers.
For example, ADNI measured CSF with Elecsys instead of
Innotest and brain volume with Freesurfer software in-
stead of FSL FIRST. However, we limited these differences
as much as possible by standardizing the biomarker values
to remove measurement levels.
Another limitation is that we used different scanners
and field strengths. This however resembles real-life
clinical practice, and we included field strength as an
additional determinant in the models. Field strength,
however, did not improve predictive ability of MRI
models. In addition, we used MMSE as a measure of
global cognition in our models, which has been de-
scribed as an insensitive instrument in preclinical
stages. Other measures for cognition (for example, a
composite score of specific items of the MMSE and
Clinical Dementia Rating scale; ADCOMS [44], or in-
strumental activities of daily living (IADL [45])) with
higher sensitivity could improve the models. Such an
approach might be subject for future studies. Lastly,
the follow-up duration varied between individuals and
the mean follow-up period of 3 ± 2 years was rather
short in comparison with the assumed duration of the
stage of preclinical AD. Nonetheless, we had enough
power to estimate risks over a period of 5 years, which
is a considerable duration of follow up.
A major strength of this study is the simplicity of the
models. Often, the goal of constructing prediction
models is to derive the most optimal combination of
many variables. However, such models often require
multiple pieces of data that are not easily available, con-
sequently limiting their clinical footprint [46]. In the
current paper, we took a different approach as we aimed
to optimize the interpretation of MRI measures and CSF
biomarkers in individuals with SCD: given that a clin-
ician has decided to obtain MRI and/or CSF biomarkers
in an individual with SCD with a given age, sex, and
MMSE, this clinician wants to make optimal use of the
results of MRI and CSF. By doing so, our models helps
to interpret biomarkers in the individual patient (hence
personalized) and shows proof of principle that person-
alized predictions could be feasible in very early stages
of AD. Another strength is that we used a large sample
of SCD individuals. All individuals had an extensive
screening at baseline to rule out MCI or other neuro-
logical causes of memory complaints and careful
follow-up, with diagnosis re-evaluated in a multidiscip-
linary setting, which has contributed to the robustness
of the data. The vast majority of individuals came to the
memory clinic with worries about their cognitive func-
tioning, rendering our models highly relevant for this
population. In fact, this population is comparable to
what in the new Alzheimer research framework is de-
scribed as clinical stage 2 [8]. Our results confirm clin-
ical validity of such stage 2, as the presence of
Alzheimer biomarkers strongly increases the risk of fu-
ture progression to MCI or dementia. Another strong
aspect of this study is that we accompany predictions
with confidence intervals, which gives a good indication
on precision of the prediction.
In an earlier study on communication of diagnostic test
results, individuals and caregivers who recently visited a
memory clinic indicated that they wanted more informa-
tion on their prognosis and what test results meant for
their personal lives (“what do these results mean for my
future”) [47]. Nonetheless, clinicians tend to be reluctant
to disclose biomarker results to cognitively normal indi-
viduals. The major concern is that disclosure could in-
crease anxiety [48]. An argument against the disclosure of
risk is the lack of treatment options. But this raises the
question whether it is ethical to withhold individuals from
information that is actually available. Moreover, our
models show that particularly the negative predictive value
of the models is good, suggesting that biomarker results
can be especially valuable to reassure patients.
Conclusions
In conclusion, we constructed prognostic models that
allow interpretation of biomarker data in cognitively
normal individuals in a memory clinic at the individual
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level. In light of future disease-modifying drugs, risk pre-
diction on an individual level becomes increasingly im-
portant [49]. By integrating biomarker results and
demographic characteristics in AD risk modeling, the
current study takes the first steps in a personalized ap-
proach for cognitively normal individuals [48, 50]. This
is especially valuable for the reassurance of individuals
with normal biomarkers, since clinical progression over
a period of 5 years is very unlikely for them.
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